Growth Metrics

Nephros (NEPH) Asset Writedowns and Impairment (2016 - 2025)

Nephros has reported Asset Writedowns and Impairment over the past 11 years, most recently at $12000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $12000.0 for Q4 2025, down 75.0% from a year ago — trailing twelve months through Dec 2025 was $68000.0 (down 74.05% YoY), and the annual figure for FY2025 was $68000.0, down 74.05%.
  • Asset Writedowns and Impairment for Q4 2025 was $12000.0 at Nephros, down from $15000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for NEPH hit a ceiling of $665000.0 in Q3 2022 and a floor of -$774000.0 in Q4 2022.
  • Median Asset Writedowns and Impairment over the past 5 years was $34000.0 (2024), compared with a mean of $17947.4.
  • Peak annual rise in Asset Writedowns and Impairment hit 2766.67% in 2021, while the deepest fall reached 1842.86% in 2021.
  • Nephros' Asset Writedowns and Impairment stood at -$122000.0 in 2021, then crashed by 534.43% to -$774000.0 in 2022, then skyrocketed by 87.73% to -$95000.0 in 2023, then skyrocketed by 150.53% to $48000.0 in 2024, then crashed by 75.0% to $12000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $12000.0 (Q4 2025), $15000.0 (Q3 2025), and $35000.0 (Q2 2025) per Business Quant data.